Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evacetrapib in high-risk vascular disease
NCT01687998Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2012
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 37
01
Overview
Phase 3, randomised, double-blind trial in cardiovascular diseases (CVD) comparing Evacetrapib with Placebo (2 arms). Primary endpoint: Composite of Cardiovascular Death, Myocardial Infarction, Stroke, Coronary Revascularization, or Hospitalization for Unstable Angina up to 4 years. Started Oct 2012; status: terminated.
02
Drugs
evacetrapib
03
Conditions
cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT01687998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01687998.